纳米结构脂质载体肺部给药研究进展  

Recent advances of nanostructured lipid carriers for pulmonary delivery

作　　者：马梦超 乔文梅 王鹤樵 唐景玲[1] MA Meng-chao;QIAO Wen-mei;WANG He-qiao;TANG Jing-ling(School of Pharmacy,Harbin Medical University,Heilongjiang Harbin,150086,China)

机构地区：[1]哈尔滨医科大学药学院,黑龙江哈尔滨150086

出　　处：《中国医院药学杂志》2021年第20期2146-2149,共4页Chinese Journal of Hospital Pharmacy

基　　金：黑龙江省自然科学基金项目(编号:H2018013);哈尔滨医科大学药学院杰出青年人才基金(编号:2019-JQ-03)。

摘　　要：传统吸入疗法不能使药物靶向到肺的特定部位,而纳米载体药物的肺部给药系统可克服传统吸入药物的不足。其中纳米结构脂质载体是固体和液体脂质的混合物经表面活性剂乳化后形成的纳米粒,具有更好的胶体稳定性和持续的药物释放行为。其组成成分具有无毒、生理惰性和生物相容性的特点,还具有良好的雾化特性,特别适用于肺部应用,并且生产过程简单(高压均质),适合大规模生产。本文介绍了常见肺部给药纳米载体,概述了纳米结构脂质载体应用于肺部的优势,为其在肺部给药领域中的深度开发提供参考。Since traditional inhalation therapy does not target drugs to specific lung regions,nano-drug carrier lung delivery system can overcome the shortcomings.Nanostructured lipid carriers(NLCs)are nanoparticles composed of a mixture of solid and liquid lipids emulsified by a surfactant.It can provide better colloidal stability with sustained drug release behavior.Furthermore,the components of NLCs are non-toxic,physiologically inert and biocompatible with excellent aerosolization performance perfect for pulmonary applications.And NLCs are suitable for mass production because of simple production process(high pressure homogenization).Here common lung drug delivery nanocarriers were introduced and their advantages summarized,providing references for the further development of NLCS in the domain of lung drug delivery.

关 键 词：纳米药物载体肺部给药系统 纳米结构脂质载体 肺部给药 安全性 

分 类 号：R944.9[医药卫生—药剂学]